Presentation is loading. Please wait.

Presentation is loading. Please wait.

Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients  Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon.

Published byChristen Bundgaard Modified over 5 years ago

Similar presentations

Presentation on theme: "Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients  Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon."— Presentation transcript:

1 Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients  Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon Lee, Jeong-Ju Yoo, Sung Hyun Ahn, Heewoo Sim, Soree Park, Hong Seok Kang, Juhee Won, Yea Na Ha, Gu-Choul Shin, So Young Kwon, Yong Kwang Park, Byeong-Sun Choi, Yun Bin Lee, Nakcheol Jeong, Yohan An, Young Seok Ju, Su Jong Yu, Hee Bok Chae, Kyung-Sang Yu, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim, Kyun-Hwan Kim  Journal of Hepatology  DOI: /j.jhep Copyright © Terms and Conditions

2 Journal of Hepatology DOI: (10.1016/j.jhep.2019.02.006)
Copyright © Terms and Conditions

3 Fig. 1 Clinical courses of 2 chronic hepatitis B patients with clinical resistance to TDF-containing regimens. Serum samples were analyzed for HBV DNA and ALT. The time points of serum sampling are indicated by arrows. ADV, adefovir dipivoxil; ALT, alanine aminotransferase; ETV, entecavir; HBV, hepatitis B virus; LAM, lamivudine; LdT, telbivudine; TDF, tenofovir disoproxil fumarate. Journal of Hepatology DOI: ( /j.jhep ) Copyright © Terms and Conditions

4 Fig. 2 In vitro tenofovir susceptibility of patient-derived RT mutants using Southern blot and quantitative real-time PCR. (A) The tenofovir susceptibility assay. Each panel shows representative autoradiograms from at least 3 independent experiments. The levels of secreted HBsAg and HBeAg were determined by ELISA to assess transfection yield. (B) Determination of IC50 values by quantitative real-time PCR. The level of HBV replication without drug treatment was set at 100%. The IC50 values were obtained by interpolation of the data from at least 3 independent experiments. HBeAg, HBV e antigen; HBsAg, HBV surface antigen; HBV, hepatitis B virus; RT, reverse transcriptase; WT, wild-type. Journal of Hepatology DOI: ( /j.jhep ) Copyright © Terms and Conditions

5 Fig. 3 In vitro tenofovir susceptibility assay and determination of the IC50 and IC90 values of tenofovir against wild-type and mutant HBV by quantitative real-time PCR. (A) A schematic representation of the mutant constructs used in this study. Commonly found HBV RT mutations and corresponding surface mutations in Clones 1–1 and 1–13 obtained were presented. (B) A tenofovir susceptibility assay was performed using Huh7 cells transfected with 2 µg of indicated HBV 1.2-mer mutants following Southern blot analysis. Each panel shows representative autoradiograms from at least 3 independent experiments. The levels of secreted HBsAg and HBeAg were determined by ELISA to assess transfection yield. (C) Determination of the IC50 and IC90 values of each HBV mutant against tenofovir treatment using quantitative real-time PCR. The level of HBV replication without drug treatment was set at 100%. The IC50 and IC90 values were obtained by interpolation of the data from at least 3 independent experiments. (D-E) Fold resistance vs. relative replication plot for each mutant. Relative viral replication (x-axis) was determined by real-time PCR in the absence of tenofovir at 4 days after Huh7 cell transfection with each mutant HBV1.2-mer. Relative resistance (y-axis) is presented as the mean fold-change in IC50 values (D) or IC90 values (E) compared to that of wild-type. The CYEI mutation had higher replication capacity with 15.3-fold increase in IC50 and 26.3-fold increase in IC90 values compared to wild-type. HBeAg, HBV e antigen; HBsAg, HBV surface antigen; HBV, hepatitis B virus; RT, reverse transcriptase. Journal of Hepatology DOI: ( /j.jhep ) Copyright © Terms and Conditions

6 Fig. 4 Susceptibility of tenofovir-resistant mutants to alternative antiviral regimens. Susceptibility to (A) entecavir, (B) entecavir plus tenofovir, and (C) a capsid assembly modulator, NVR Determination of the IC50 values of each HBV mutant against treatment with indicated drugs. Huh7 cells were transfected with 2 µg of indicated HBV1.2-mer mutants. At 4 days after transfection, cells were prepared and subjected to Southern blot analysis. The level of HBV replication without drug treatment was set at 100%. The IC50 values were obtained by interpolation of the data from at least 3 independent experiments. In vitro susceptibility assay of indicated HBV mutants to treatment with (A) entecavir, (B) entecavir plus tenofovir combination, or (C) a capsid assembly modulator, NVR HBeAg, HBV e antigen; HBsAg, HBV surface antigen; HBV, hepatitis B virus; WT, wild-type. Journal of Hepatology DOI: ( /j.jhep ) Copyright © Terms and Conditions

Download ppt "Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients  Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon."

Similar presentations

Jung Min Lee, Sang Hoon Ahn, Hyon Suk Kim, Hana Park, Hye Young Chang, Do Young Kim, Seong Gyu Hwang, Kyu Sung Rim, Chae Yoon Chon, Kwang-Hyub Han, and.

Jung Min Lee, Sang Hoon Ahn, Hyon Suk Kim, Hana Park, Hye Young Chang, Do Young Kim, Seong Gyu Hwang, Kyu Sung Rim, Chae Yoon Chon, Kwang-Hyub Han, and.
Copyright © 2016 McGraw-Hill Education. All rights reserved.

Copyright © 2016 McGraw-Hill Education. All rights reserved.
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.

Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.
Publication stage: In Press Accepted Manuscript

Publication stage: In Press Accepted Manuscript
Discrepancy in perceptions regarding patient participation in hand hygiene between patients and health care workers  Min-Kyung Kim, MD, Eun Young Nam,

Discrepancy in perceptions regarding patient participation in hand hygiene between patients and health care workers  Min-Kyung Kim, MD, Eun Young Nam,
MP16-14 CLINICAL IMPLICATION OF METASTASECTOMY IN METACHRONOUS METASTATIC RENAL CELL CARCINOMA IN THE ERA OF TARGETED THERAPY  Jong Won Kim, Jongsoo Lee,

MP16-14 CLINICAL IMPLICATION OF METASTASECTOMY IN METACHRONOUS METASTATIC RENAL CELL CARCINOMA IN THE ERA OF TARGETED THERAPY  Jong Won Kim, Jongsoo Lee,
Volume 150, Issue 6, Pages (December 2016)

Volume 150, Issue 6, Pages (December 2016)
Volume 67, Issue 2, Pages (August 2017)

Volume 67, Issue 2, Pages (August 2017)
Volume 130, Issue 3, Pages (March 2006)

Volume 130, Issue 3, Pages (March 2006)
Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B  Hye Soo Kim, Beom Kyung Kim,

Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B  Hye Soo Kim, Beom Kyung Kim,
Volume 148, Issue 2, Pages e7 (February 2015)

Volume 148, Issue 2, Pages e7 (February 2015)
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation  Ji Eun Uhm, Kihyun Kim, Tae Kyu Lim, Byeong-Bae.

Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation  Ji Eun Uhm, Kihyun Kim, Tae Kyu Lim, Byeong-Bae.
Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation.

Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation.
Volume 44, Issue 2, Pages (February 2006)

Volume 44, Issue 2, Pages (February 2006)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Immune-driven adaptation of hepatitis B virus genotype D involves preferential alteration in B-cell epitopes and replicative attenuation—an insight from.

Immune-driven adaptation of hepatitis B virus genotype D involves preferential alteration in B-cell epitopes and replicative attenuation—an insight from.
Hyoung Yoon Chang, MD, PhD, MPH, Dong In Suh, MD, Song-I

Hyoung Yoon Chang, MD, PhD, MPH, Dong In Suh, MD, Song-I
DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic.

DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Similar presentations

Ads by Google